A randomized controlled trial comparing the clinical efficacy and cost-effectiveness of eye movement desensitization and reprocessing (EMDR) and integrated EMDR-Dialectical Behavioural Therapy (DBT) in the treatment of patients with post-traumatic stress disorder and comorbid (Sub)clinical borderline personality disorder: study design

Aishah Snoek, Aartjan T F Beekman, Jack Dekker, Inga Aarts, Gerard van Grootheest, Matthijs Blankers, Chris Vriend, Odile van den Heuvel, Kathleen Thomaes, Aishah Snoek, Aartjan T F Beekman, Jack Dekker, Inga Aarts, Gerard van Grootheest, Matthijs Blankers, Chris Vriend, Odile van den Heuvel, Kathleen Thomaes

Abstract

Background: Comorbidity between Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD) is high. There is growing motivation among clinicians to offer PTSD treatments - such as Eye Movement Desensitization and Reprocessing (EMDR) - to patients with PTSD and comorbid BPD. However, a large subgroup with comorbid BPD does not sufficiently respond to PTSD treatment and is more likely to be excluded or to dropout from treatment. Dialectical Behaviour Therapy (DBT) for BPD is well established and although there is some evidence that DBT combined with DBT Prolonged Exposure (DBT + DBT PE) is twice as effective in reducing PTSD symptoms than DBT alone, the comparative efficacy of integrated PTSD-DBT and PTSD-only treatment has not been investigated yet. The current study will therefore evaluate the comparative clinical efficacy and cost-effectiveness of EMDR-DBT and EMDR-only in patients with PTSD and comorbid (sub)clinical BPD. Moreover, it is not clear yet what treatment works best for which individual patient. The current study will therefore evaluate neurobiological predictors and mediators of the individual response to treatment.

Method: A randomized controlled trial comparing the clinical efficacy and cost-effectiveness of integrated EMDR-DBT (n = 63) and EMDR-only (n = 63) in treatment-seeking adult patients with PTSD and comorbid (sub)clinical BPD. In addition, neurobiological predictors and mediators of treatment outcome, such as hair cortisol, FKBP5 and BDNF protein levels and FKBP5 and BDNF methylation status, are measured through hair and blood samples.

Discussion: This is the first study to compare the clinical efficacy and cost-effectiveness of integrated EMDR-DBT and EMDR-only in patients with PTSD and comorbid (sub)clinical BPD, while simultaneously identifying individual predictors and mediators of treatment response. Results will reveal which treatment works best for which individual patient, thereby guiding individual treatment choices and personalizing psychiatry.

Trial registration: Clinical Trials, NCT03833453 . Retrospectively registered, 15 March 2019.

Keywords: Borderline personality disorder; Dialectical behaviour therapy; EMDR; PTSD.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig. 1
Fig. 1
Flow chart for the study design
Fig. 2
Fig. 2
Flow diagram of the expected study progress throughout enrolment and assignment to the interventions
Fig. 3
Fig. 3
Treatment outline per week for the EMDR-only condition and the EMDR-DBT condition
Fig. 4
Fig. 4
Relationship between treatment condition (i.e. EMDR, EMDR-DBT) and primary outcome measures (i.e. post-treatment scores on the CAPS-5 and SCID-5-PD), proposedly mediated by pre-to post-stressor changes in levels of cortisol, FKBP5 and BDNF protein levels and FKBP5 and BDNF methylation status. It is hypothesized that the regression of the primary outcome measures on treatment condition, ignoring the mediators, will be significant (c1). Secondly, the regression of the mediators cortisol, FKBP5 and BDNF protein levels and FKBP5 and BDNF methylation status on treatment condition are hypothesized to be significant as well (a1, a2 and a3 resp.). In addition, the regression of the primary outcome measures on the mediators are also expected to be significant (b1, b2 and b3 resp.). Lastly, it is hypothesized that, when controlling for the mediators, treatment condition will significantly predict the scores on the CAPS-5 and SCID-5-PD, supporting partial mediation

References

    1. Kilpatrick DG, Resnick HS, Milanak ME, Miller MW, Keyes KM, Friedman MJ. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 criteria. J Trauma Stress. 2013;26(5):537–547.
    1. Ljungqvist I, Topor A, Forssell H, Svensson I, Davidson L. Money and mental illness: a study of the relationship between poverty and serious psychological problems. Community Ment Health J. 2016;52(7):842–850.
    1. Kartha A, Brower V, Saitz R, Samet JH, Keane TM, Liebschutz J. The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med Care. 2008;46(4):388.
    1. Walker EA, Katon W, Russo J, Ciechanowski P, Newman E, Wagner AW. Health care costs associated with posttraumatic stress disorder symptoms in women. Arch Gen Psychiatry. 2003;60(4):369–374.
    1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, et al. Disability and quality of life impact of mental disorders in Europe: results from the European. Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand. 2004;109:38–46.
    1. Shapiro F. Eye movement desensitization and reprocessing (EMDR) therapy: Basic principles, protocols, and procedures. New York: Guilford Publications; 2017.
    1. Bisson JI, Roberts NP, Andrew M, Cooper R, Lewis C. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;12.
    1. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 2007;190(2):97–104.
    1. Moreno-Alcázar A, Treen D, Valiente-Gómez A, Sio-Eroles A, Pérez V, Amann BL, Radua J. Efficacy of eye movement desensitization and reprocessing in children and adolescent with post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Front Psychol. 2017;8:1750.
    1. Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatr. 2005;162(2):214–227.
    1. Chen YR, Hung KW, Tsai JC, Chu H, Chung MH, Chen SR, Chou KR. Efficacy of eye-movement desensitization and reprocessing for patients with posttraumatic-stress disorder: a meta-analysis of randomized controlled trials. PLoS One. 2014;9(8).
    1. Feeny NC, Zoellner LA, Foa EB. Treatment outcome for chronic PTSD among female assault victims with borderline personality characteristics: a preliminary examination. J Personal Disord. 2002;16(1):30–40.
    1. Forbes D, Creamer M, Allen N, Elliott P, McHugh T, Debenham P, Hopwood M. The MMPI-2 as a predictor of symptom change following treatment for posttraumatic stress disorder. J Pers Assess. 2002;79(2):321–336.
    1. Snoek A, Nederstigt J, Sijbrandij M, Lok A, Cuijpers P, Thomaes K. Predictive value of personality disorders for treatment response in psychotherapy for posttraumatic stress disorder. 2020.
    1. Frías Á, Palma C. Comorbidity between post-traumatic stress disorder and borderline personality disorder: a review. Psychopathology. 2015;48(1):1–10.
    1. Dorrepaal E, Thomaes K, Hoogendoorn AW, Veltman DJ, Draijer N, van Balkom AJ. Evidence-based treatment for adult women with child abuse-related complex PTSD: a quantitative review. Eur J Psychotraumatol. 2014;5(1):23613.
    1. Pagura J, Stein MB, Bolton JM, Cox BJ, Grant B, Sareen J. Comorbidity of borderline personality disorder and posttraumatic stress disorder in the US population. J Psychiatr Res. 2010;44(16):1190–1198.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5. Washinton, DC: Author; 2013.
    1. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2011;377(9759):74–84.
    1. Ellison WD, Rosenstein L, Chelminski I, Dalrymple K, Zimmerman M. The clinical significance of single features of borderline personality disorder: Anger, affective instability, impulsivity, and chronic emptiness in psychiatric outpatients. J Personal Disord. 2016;30(2):261–270.
    1. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet. 2004;364(9432):453–461.
    1. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, et al. Two-year randomized controlled trial and follow-up of dialectical behaviour therapy vs therapy by experts for suicidal behaviours and borderline personality disorder. Arch Gen Psychiatry. 2006;63(7):757–766.
    1. Wong J, Bahji A, Khalid-Khan S. Psychotherapies for adolescents with subclinical and borderline personality disorder: a systematic review and meta-analysis. Can J Psychiatr. 2020;65(1):5–15.
    1. Harned MS, Jackson SC, Comtois KA, Linehan MM. Dialectical behaviour therapy as a precursor to PTSD treatment for suicidal and/or self-injuring women with borderline personality disorder. J Trauma Stress. 2010;23(4):421–429.
    1. Bohus M, Dyer AS, Priebe K, Krüger A, Kleindienst N, Schmahl C, et al. Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomised controlled trial. Psychother Psychosom. 2013;82(4):221–233.
    1. Brettschneider C, Riedel-Heller S, König HH. A systematic review of economic evaluations of treatments for borderline personality disorder. PLoS One. 2014;9(9):e107748.
    1. Harned MS, Korslund KE, Foa EB, Linehan MM. Treating PTSD in suicidal and self-injuring women with borderline personality disorder: development and preliminary evaluation of a dialectical behavior therapy prolonged exposure protocol. Behav Res Ther. 2012;50(6):381–386.
    1. Harned MS, Korslund KE, Linehan MM. A pilot randomized controlled trial of dialectical behaviour therapy with and without the dialectical behaviour therapy prolonged exposure protocol for suicidal and self-injuring women with borderline personality disorder and PTSD. Behav Res Ther. 2014;55:7–17.
    1. Bohus M, Schmahl C, Fydrich T, Steil R, Müller-Engelmann M, Herzog J, Ludäscher P, Kleindienst N, Priebe K. A research programme to evaluate DBT-PTSD, a modular treatment approach for complex PTSD after childhood abuse. Borderline Personal Disord Emot Dysregul. 2019;6(1):7.
    1. de Bont PA, Van Der Vleugel BM, van den Berg DP, De Roos C, Lokkerbol J, Smit F, de Jongh A, van der Gaag M, van Minnen A. Health–economic benefits of treating trauma in psychosis. Eur J Psychotraumatol. 2019;10(1):1565032.
    1. Yehuda R. In Anxiety and anxiolytic drugs. Berlin, Heidelberg: Springer; 2005. Neuroendocrine aspects of PTSD; pp. 371–403.
    1. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017;18(3):162–214.
    1. Morris MC, Compas BE, Garber J. Relations among posttraumatic stress disorder,comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev. 2012;32(4):301–315.
    1. Meewisse ML, Reitsma JB, De Vries GJ, Gersons BP, Olff M. Cortisol and post- traumatic stress disorder in adults: systematic review and meta-analysis. Br J Psychiatry. 2007;191(5):387–392.
    1. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, Ising M, et al. Gene expression patterns associated with posttraumatic stress disorder following exposure to the world trade center attacks. Biol Psychiatry. 2009;66(7):708–711.
    1. Olff M, de Vries GJ, Güzelcan Y, Assies J, Gersons BP. Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinol. 2007;32(6):619–626.
    1. Ruocco AC, Carcone D. A neurobiological model of borderline personality disorder: systematic and integrative review. Harv Rev Psychiatry. 2016;24(5):311–329.
    1. Wingenfeld K, Driessen M, Adam B, Hill A. Overnight urinary cortisol release in women with borderline personality disorder depends on comorbid PTSD and depressive psychopathology. Eur Psychiatry. 2007;22(5):309–312.
    1. Southwick SM, Axelrod SR, Wang S, Yehuda R, Morgan CA, III, Charney D, et al. Twenty-four-hour urine cortisol in combat veterans with PTSD and comorbid borderline personality disorder. J Nerv Ment Dis. 2003;191(4):261–262.
    1. Gow R, Thomson S, Rieder M, Van Uum S, Koren G. An assessment of cortisol analysis in hair and its clinical applications. Forensic Sci Int. 2010;196(1–3):32–37.
    1. Russell E, Koren G, Rieder M, Van Uum S. Hair cortisol as a biological marker of chronic stress: current status, future directions and unanswered questions. Psychoneuroendocrinology. 2012;37(5):589–601.
    1. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34:S186–S195.
    1. Gillespie CF, Phifer J, Bradley B, Ressler KJ. Risk and resilience: genetic and environmental influences on development of the stress response. Depress Anxiety. 2009;26(11):984–992.
    1. Sarapas C, Cai G, Bierer LM, Golier JA, Galea S, Ising M, et al. Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis Markers. 2011;30(2, 3):101–110.
    1. Yehuda R, Daskalakis NP, Bierer LM, Bader HN, Klengel T, Holsboer F, Binder EB. Holocaust exposure induced intergenerational effects on FKBP5 methylation. Biol Psychiatry. 2016;80(5):372–380.
    1. Young DA, Inslicht SS, Metzler TJ, Neylan TC, Ross JA. The effects of early trauma and the FKBP5 gene on PTSD and the HPA axis in a clinical sample of gulf war veterans. Psychiatry Res. 2018.
    1. Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner A, Koch E, et al. Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. Front Psychiatry. 2013;4:118.
    1. Bishop JR, Lee AM, Mills LJ, Thuras PD, Eum S, Clancy D, Lim KO. Methylation of FKBP5 and SLC6A4 in relation to treatment response to mindfulness based stress reduction for posttraumatic stress disorder. Front Psychiatry. 2018;9:418.
    1. Rakofsky JJ, Ressler KJ, Dunlop BW. BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Mol Psychiatry. 2012;17(1):22.
    1. Perroud N, Salzmann A, Prada P, Nicastro R, Hoeppli ME, Furrer S, et al. Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry. 2013;3(1):e207.
    1. Park SC, Park YC, Lee MS, Chang HS. Plasma brain-derived neurotrophic factor level may contribute to the therapeutic response to eye movement desensitisation and reprocessing in complex post-traumatic stress disorder: a pilot study. Acta Neuropsychiatrica. 2012;24(6):384–386.
    1. Twisk JWR. Applied longitudinal data analysis for epidemiology: a practical guide. UK: Cambridge University Press; 2007.
    1. Imel ZE, Laska K, Jakupcak M, Simpson TL. Meta-analysis of dropout in treatments for posttraumatic stress disorder. J Consult Clin Psychol. 2013;81(3):394.
    1. Kliem S, Kröger C, Kosfelder J. Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling. J Consult Clin Psychol. 2010;78(6):936.
    1. Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, Marx BP, Keane TM. The clinician-administered PTSD scale for DSM-5 (CAPS-5) 2013.
    1. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The ptsd checklist for dsm-5 (pcl-5) 2013.
    1. Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489–498.
    1. Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, et al. The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): Development and initial psychometric evaluation in military veterans. 2017.
    1. First MB, Williams JB, Benjamin LS, Spitzer RL. Structured clinical interview for DSM-5 personality disorders: SCID-5-PD. Arlington, VA: American Psychiatric Association Publishing; 2016.
    1. Maffei C, Fossati A, Agostoni I, Barraco A, Bagnato M, Deborah D, et al. Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. J Personal Disord. 1997;11(3):279–284.
    1. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the structured clinical interview for DSM-IV Axis I disorders (SCID I) and Axis II disorders (SCID II) Clin Psychol Psychother. 2011;18(1):75–79.
    1. Weertman A, ArntZ A, Dreessen L, Velzen CV, Vertommen S. Short-interval test-retest interrater reliability of the Dutch version of the Structured Clinical Interview for DSM-IV personality disorders (SCID-II) J Personal Disord. 2003;17(6):562–567.
    1. Somma A, Borroni S, Maffei C, Besson E, Garbini A, Granozio S, et al. Inter-rater reliability of the Italian translation of the structured clinical interview for DSM-5 personality disorders (SCID-5-PD): a study on consecutively admitted clinical adult participants. J Psychopathol. 2017;23:105–111.
    1. First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5—research version (SCID-5 for DSM-5, research version; SCID-5 RV) Arlington, VA: American Psychiatric Association; 2015.
    1. Associaction AP. SCID-5-S Gestructureerd klinisch interview voor DSM-5 Syndroomstoornissen. Amsterdam: Boom; 2017.
    1. Shankman SA, Funkhouser CJ, Klein DN, Davila J, Lerner D, Hee D. Reliability and validity of severity dimensions of psychopathology assessed using the structured clinical interview for DSM-5 (SCID) Int J Methods Psychiatr Res. 2018;27(1):e1590.
    1. Lambert MJ, Burlingame GM, Umphress V, Hansen NB, Vermeersch DA, Clouse GC, Christopherson C, Burlingame GM. The reliability and validity of the outcome questionnaire. Clin Psychol Psychother. 1996;3(4):249–258.
    1. De Jong K, Nugter MA, Polak MG, Wagenborg JE, Spinhoven P, Heiser WJ. The outcome questionnaire (OQ-45) in a Dutch population: a cross-cultural validation. Clin Psychol Psychother. 2007;14(4):288–301.
    1. Morey LC. Personality assessment inventory. Odessa, FL: Psychological Assessment Resources; 1991.
    1. Distel MA, de Moor MH, Boomsma DI. Nederlandse vertaling van de Personality Assessment Inventory-Borderline kenmerken schaal (PAI-BOR): normgegevens, factorstructuur en betrouwbaarheid. Psychologie en Gezondheid. 2009;37(1):38–46.
    1. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess. 2004;26(1):41–54.
    1. Spielberger CD, Jacobs G, Russell S, Crane R. Assessment of anger: the state-trait anger scale. Adv Pers Assess. 1983;2:159–187.
    1. Van der Ploeg HM, Defares PB, Spielberger CD. Handleiding bij de Zelf-analyse Vragenlijst, ZAV [manual for the self-analysis questionnaire, ZAV] Lisse, NL: Swets & Zeitlinger; 1982.
    1. Kroner DG, Reddon JR. The anger expression scale and state-trait anger scale: stability, reliability, and factor structure in an inmate sample. Crim Justice Behav. 1992;19(4):397–408.
    1. Baetens I, Claes L, Onghena P, Grietens H, Van Leeuwen K, Pieters C, et al. Non-suicidal self-injury in adolescence: a longitudinal study of the relationship between NSSI, psychological distress and perceived parenting. J Adolesc. 2014;37(6):817–826.
    1. Muehlenkamp JJ, Claes L, Havertape L, Plener PL. International prevalence of adolescent non-suicidal self-injury and deliberate self-harm. Child Adolesc Psychiatry Ment Health. 2012;6(1):10.
    1. Hakkaart-van Roijen, L., Straten, A. V., Tiemens, B., & Donker, M. C. H. (2002). Handleiding Trimbos/iMTA questionnaire for costs associated with psychiatric illness (TiC-P) (no. iMTA series; 02.61). Institute of Medical Technology Assessment (iMTA).
    1. Bouwmans C, De Jong K, Timman R, Zijlstra-Vlasveld M, Van der Feltz-Cornelis C, Tan SS, Hakkaart-van RL. Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiCP) BMC Health Serv Res. 2013;13(1):217.
    1. Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736.
    1. Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–715.
    1. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res. 2013;22(7):1717–1727.
    1. Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88:815–823.
    1. Geeta A, Jamaiyah H, Safiza MN, Khor GL, Kee CC, Ahmad AZ, et al. Reliability, technical error of measurements and validity of instruments for nutritional status assessment of adults in Malaysia. Singap Med J. 2009;50(10):1013.
    1. Winstein CJ, Pohl PS, Cardinale C, Green A, Scholtz L, Waters CS. Learning apartial-weight-bearing skill: effectiveness of two forms of feedback. Phys Ther. 1996;76(9):985–993.
    1. Manenschijn L, Koper JW, Lamberts SW, van Rossum EF. Evaluation of a method to measure long term cortisol levels. Steroids. 2011;76(10–11):1032–1036.
    1. Pierzchała K, Łabuz-Roszak B. Selected methods for evaluating the autonomic nervous system. Wiad Lek. 2002;55(5-6):325–331.
    1. Jaradeh SS, Prieto TE. Evaluation of the autonomic nervous system. Phys Med Rehabil Clin. 2003;14(2):287–305.
    1. Korn DL, Maxfield L, Smyth NJ, Stickgold R. EMDR fidelity rating scale (EFRS) 2017.
    1. Linehan MM. Korslund KE. Dialectical Behavior Therapy Adherence Manual: University of Washington; 2003.
    1. Linehan MM. Cognitive-Behavioural treatment of borderline personality disorder. New York: Guilford Press; 1993.
    1. Schafer JL, Olsen MK. Multiple imputation for multivariate missing-data problems: a data analyst's perspective. Multivar Behav Res. 1998;33(4):545–571.
    1. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness Resour Allocation. 2013;11(1):6.
    1. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II—an ISPOR good research practices task force report. Value Health. 2015;18(2):161–172.
    1. Nederland Z. Guideline for economic evaluations in healthcare. Diemen: ZIN; 2016.
    1. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford university press; 2015.
    1. Richardson J. Cost utility analysis: what should be measured? Soc Sci Med. 1994;39(1):7–21.
    1. World Medical Association World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373.
    1. Knekt P, Lindfors O, Keinänen M, Heinonen E, Virtala E, Härkänen T. The prediction of the level of personality organization on reduction of psychiatric symptoms and improvement of work ability in short-versus long-term psychotherapies during a 5-year follow-up. Psychol Psychother Theory Res Pract. 2017;90(3):353–376.
    1. Maljanen T, Knekt P, Lindfors O, Virtala E, Tillman P, Härkänen T. & Helsinki Psychotherapy Study Group. The cost-effectiveness of short-term and long-term psychotherapy in the treatment of depressive and anxiety disorders during a 5-year follow-up. J Affect Disord. 2016;190:254–263.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere